Pfizer RG3039 Program for Spinal Muscular Atrophy Reaches Development Milestone
Originally published on September 4, 2013. Reaching the first milestone was triggered by completion of specific program activities and coincides with the successful completion of all transition obligations to Pfizer by Repligen. Click here for the Repligen press release. Repligen Corporation announced today that it has achieved a milestone from Pfizer, Inc. under the terms […]
Pfizer RG3039 Program for Spinal Muscular Atrophy Reaches Development Milestone Read More »

